Brand & Marketing

UniQure sells hemophilia gene therapy royalty rights

UniQure made an announcement that it has sold a portion of the royalties worth $400 million it expects to get from the...

Latest news

Merck Signs $493M Agreement to Use Cyprumed’s Oral Peptide Platform

Merck & Co. is taking a significant step toward transforming its peptide therapies into convenient oral tablets through a...

The late-stage research of Bristol Myers’ heart disease medication falls short of its primary objectives

Bristol Myers Squibb disclosed that its drug stavartanate did not successfully improve functional capacity or symptom intensities in heart...

J&J MedTech presents the first Ottava surgical robot clinical cases

Johnson & Johnson MedTech successfully conducted the initial clinical use of Ottava surgical robot through a minimally invasive gastric...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you

FDA Rejects Supernus Pharmaceuticals’ SPN-830 Application

Supernus Pharmaceuticals Inc. has announced that the...

Corcept’s ALS Modulator Fails to Meet Primary Endpoint in Phase 2 Study

After Amylyx and PTC, Corcept has also decided to...

Pfizer and Arvinas disclose mixed breast cancer survival findings for PROTAC degrader

Pfizer and Arvinas reported that their estrogen receptor degrader...